Prescription Opioid Abuse - Pfizer Medical Information
Post on 03-Dec-2021
1 Views
Preview:
Transcript
Prescription Opioid Abuse: Working together to address a public health concern
For your personal use. Not for further distribution
Content of presentation
• The problem of prescription opioid misuse, abuse, and diversion
• Who is at risk for opioid misuse and abuse? • What is being done to reduce the risk of opioid
abuse? • A pharmaceutical industry approach:
Abuse-deterrent opioids
For your personal use. Not for further distribution
The Problem of Prescription Opioid Misuse, Abuse, and Diversion
For your personal use. Not for further distribution
The important role of prescription opioids
~100 million adult Americans are affected by a chronic pain condition1
Patients deserve access to effective medications to treat pain, including prescription opioids when appropriate1
1. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.
For your personal use. Not for further distribution
There is potential for misuse, abuse, and diversion of prescription opioids
Removing a medicine from legitimate circulation: can involve sharing, purchasing, and theft among family and friends
Any use of an illicit drug or use of a prescription drug for a nonmedical purpose
Use of a medicine other than as directed or as indicated to treat an illness
Misuse
Abuse
Diversion
Webster LR, Fine PG. J Pain. 2010;11(7):602–11. Webster L, et al. J Opioid Manag. 2011;7(3):235–45.
For example:
Sharing prescription opioids among friends or family
Ingesting medicine to get high
Taking more than your prescribed dose
For your personal use. Not for further distribution
Increased use of opioids in treating pain has led to a significant rise in prescriptions
Adapted from: Centers for Disease Control and Prevention. Prescription drug abuse and overdose: public health perspective. www.cdc.gov/primarycare/materials/opoidabuse/docs/pda-phperspective-508.pdf. Published October 24, 2012. Accessed December 3, 2015. Data from: Source™ Prescription Audit (SPA) and IMS Health Vector One®: National (VONA).
In 2011, the number of pharmacy prescriptions for opioids nearly tripled
Rise in Prescription Opioids
+175% 1991–2011
219 million
2011
76 million
1991
For your personal use. Not for further distribution
Prescription opioid misuse and abuse are associated with serious health consequences
In 2013, 44 people died from opioid overdoses every single day
Deaths from unintentional and intentional overdose of prescription opioids1,2
+300% 1999–2013
1. Centers for Disease Control and Prevention. Deaths from prescription opioid overdose. www.cdc.gov/drugoverdose/data/overdose.html. Updated October 16, 2015. Accessed December 3, 2015.
2. Centers for Disease Control and Prevention. MMWR Morbid Mortal Weekly Rep. 2013;62(12):234.
16,235
2013
4030
1999
The number of opioid overdose deaths quadrupled
For your personal use. Not for further distribution
Opioid overdose deaths are only the tip of the iceberg
In 2010, for every 1 opioid overdose death there were…
*Treatment admissions are for primary use of opioids from the Treatment Exposure Data Set. †Emergency department visits are from the Drug Abuse Warning Network (https://dawninfo.samhsa.gov/default.asp). ‡Abuse/dependence in the past year and nonmedical use in the past month are from the 2012 National Survey on Drug Use and Health. Centers for Disease Control and Prevention. Prescription drug abuse and overdose: public health perspective. www.cdc.gov/primarycare/materials/opoidabuse/docs/pda-phperspective-508.pdf. Published October 24, 2012. Accessed December 3, 2015.
who abused/were dependent‡
abuse treatment admissions* emergency department visits†
nonmedical users‡
10 26
108 733
For your personal use. Not for further distribution
Oral ingestion is the major route of abuse, but injection and inhalation are the most dangerous
Oral (chewed
and whole) 92% Inhalation
5% (includes snorting)
Injection 3%
Routes of abuse
• Higher rates of major health effects* or death are associated with inhalation (10.2%) and injection (16.5%) compared with oral ingestion (8.6%)1
• Injecting may result in rise in blood-borne infections (HIV, hepatitis C)
*Major health effect refers to symptoms that are life threatening or result in residual disability. 1. Katz N, et al. Am J Drug Alcohol Abuse. 2011;37(4):205–17.
For your personal use. Not for further distribution
Extended Release (ER) opioids are tampered with for purposes of misuse and abuse
55 38 47 53 62 25 6 <1 <1 36 9 46 0
20
40
60
80
ER oxycodone ER oxymorphone ER morphine
Pers
ons
abus
ing,
%
Oral Snorting Smoking Injecting
Nonoral routes of abuse are common with ER opioids*
ER, extended release. Percentages for each drug (also shown as text in bars) do not add up to 100% because respondents could report multiple routes of administration. *Before introduction of reformulated ER oxycodone and ER oxymorphone. Adapted from: Butler SF, et al. J Pain. 2013;14(4):351–8.
This data was collected from a sample of individuals who were at risk for opioid abuse and assessed for substance abuse treatment
For your personal use. Not for further distribution
Who Is at Risk for Opioid Misuse and Abuse?
For your personal use. Not for further distribution
Misuse or abuse of prescription opioids can happen to anyone
~1 out of 5 patients misuse or abuse their opioid medications1
Anyone, regardless of age, sex, race, ethnicity, income, or educational level, is at risk for prescription opioid misuse or abuse
Patients with chronic pain are susceptible: an estimated 50–80% of people who die from prescription opioid overdoses have a history of chronic pain2
1. Vowles KE, et al. Pain. 2015;156(4):569–76. 2. US Department of Health and Human Services. Addressing prescription drug abuse in the United States. www.cdc.gov/drugoverdose/pdf/hhs_prescription_drug_abuse_report_09.2013.pdf. Published September 2013. Accessed December 3, 2015.
For your personal use. Not for further distribution
Free from friend or
relative, 53%
Bought/taken from friend or relative, 15%
Drug dealer or stranger, 4%
Internet, 0%
Other,† 4% 1 doctor, 21%
>1 doctor, 3%
~70% of nonmedical users of prescription opioids obtain them from friends or relatives*
*Nonmedical use is defined as “using without a prescription of the individual’s own or simply for the experience or feeling the drugs caused.” †Includes “wrote fake prescription,” “stole from doctor’s office/clinic/hospital/pharmacy,” and “some other way.” Adapted from: Center for Behavioral Health Statistics and Quality. Results From the 2013 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. http://archive.samhsa.gov/data/NSDUH/2013SummNatFindDetTables/DetTabs/NSDUH-DetTabsSect6peTabs1to54-2013.htm#tab6.47b. Accessed December 3, 2015. For your personal use. Not for further distribution
What Is Being Done to Reduce the Risk of Opioid Abuse?
For your personal use. Not for further distribution
Health care professionals
State government
Federal government Pharmaceutical industry
• Avoid overprescribing • Risk assessment for
patient opioid abuse • Patient
medication/drug monitoring
• Drug abuse treatment programs
• Opioid prescribing guidelines
• Prescription Drug Monitoring Programs
• Naloxone availability • Targeting “pill mills” • Opioid prescribing
rules
• White House Prescription Drug Abuse Prevention Plan
• FDA guidance on the development of abuse-deterrent opioids
• CDC draft guidelines for Opioids prescribing
• Development of abuse-deterrent opioids
• Nationwide education programs
Groups are taking specific actions against prescription opioid abuse
FDA, US Food and Drug Administration.
For your personal use. Not for further distribution
Law enforcement
Patients and advocacy groups
Educational institutions
Managed care
• Prevention of illegal drug distribution
• Appropriate disposal of opioids
• Abuse awareness • Appropriate use,
storage, and disposal of opioids
• Advocacy for patient access to medications
• Youth and teacher education, with a focus on prevention
• Monitoring for opioid misuse or abuse
• Patient access to abuse-deterrent opioids
Groups are taking specific actions against prescription opioid abuse (cont’d)
For your personal use. Not for further distribution
One approach health care providers can utilize to standardize their prescribing practice*
*Once other treatments have been tried and the decision has been made to initiate opioid therapy, a standardized set of steps should be applied to all patients. As of yet, there is no empirical evidence of the effectiveness of universal precautions in reducing the abuse of prescription opioids or the outcomes related to the misuse, abuse, or diversion of prescription opioids.
Dialogue
with patient
3 Assess
risk
1 Select agent
2 Monitor
treatment
4
Assess how likely the patient is to abuse opioid medication
Choose the right medication for the
patient. If opioids are appropriate, consider an abuse-deterrent
opioid
Before starting medication, let the patient know about benefits and risks
of medication through a patient written agreement
Continue to see the patient to assess
whether the medication works, that the side
effects are minimal, and whether the patient is
using the medication as prescribed
For your personal use. Not for further distribution
A Pharmaceutical Industry Approach: Abuse-Deterrent Opioids
For your personal use. Not for further distribution
Physical/chemical barrier*
Agonist/antagonist combination*
Abuse-deterrent opioids are designed to provide the same pain relief, while providing an obstacle against tampering
*Only 2 types of abuse-deterrent formulations are shown; others are described in the FDA guidance. US Department of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research. Abuse-Deterrent Opioids—Evaluation and Labeling. Guidance for Industry. Silver Spring, MD: US Food and Drug Administration; 2015. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf. Accessed December 3, 2015.
“One potentially important step towards the goal of creating safer opioid analgesics has been the development of opioids that are formulated to deter abuse. FDA considers the development of these products a high public health priority.”
Abuse-deterrent opioids do not address all routes of abuse, but are an important approach
Some examples of Types of Abuse deterrent technology:
For your personal use. Not for further distribution
Several opioids with physical/chemical abuse-deterrent technology are currently on the market
Abuse-deterrent technology: physical/chemical approach
• Opioids with physical and/or chemical barriers have built-in properties that make the pills difficult to crush, chew, or dissolve
• This aims to deter abuse through intranasal and intravenous routes of administration
Images are from: Abuse-deterrent opioids advances in technology. Pain Medicine News. 2015. www.painmedicinenews.com/download/BB157_WM.pdf. Accessed December 3, 2015.
Crushed gelatin capsule Crush-resistant tablet
For your personal use. Not for further distribution
Abuse-deterrent technology: example of an agonist/antagonist approach
• The agonist/antagonist combination contains an isolated antagonist (eg, naltrexone) at the core
• When taken as directed, the antagonist is not released • Upon tampering (chewing, crushing), the antagonist is released
and causes a reduction in euphoric effects (eg, high) of the opioid (agonist)
At least one opioid with an agonist/antagonist abuse-deterrent design is on the market
Opioid
Antagonist core
Extended-release coating
For your personal use. Not for further distribution
• Prescription opioid abuse is a significant public health concern with serious health and economic consequences
• Reducing opioid abuse may involve multiple approaches
Summary
Reducing opioid abuse
Law enforcement efforts
Patient advocacy
State/federal efforts
Use of medications, including abuse-deterrent opioids
Prescriber education and treatment
guidelines
Drug treatment programs
For your personal use. Not for further distribution
top related